Roman Shinder is an Ophthalmology physician affiliated with SUNY Downstate Health Sciences University. OpenAlex indexes 190 publications with 1,479 citations (h-index 21).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
24208a Oak Park Dr
Little Neck, NY 113622621
Telephone
917-710-7627Registry record last updated 2 Aug 2010.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year202530 payments$26,223openpaymentsdata.cms.gov ↗
- Bausch & Lomb Americas Inc.Program year20251 payment
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
79.9%Macrolide79.9%Erythromycin100%Part D≥198 patientsSensory organs
16.2%Aminoglycoside Antibacterial11.6%Neomycin-Polymyxin-Dexameth100%Part D≥19 patientsProstaglandin Analog4.6%Latanoprost100%Part D<11 patientsMetabolism & gastrointestinal
3.9%Corticosteroid3.9%Prednisone100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease
Ophthalmic Plastic and Reconstructive Surgery
2023 - Cemiplimab for Orbital Squamous Cell Carcinoma in 11 Cases
Ophthalmic Plastic and Reconstructive Surgery
2022 - Outcomes of Patients With Thyroid Eye Disease Partially Treated With Teprotumumab
Ophthalmic Plastic and Reconstructive Surgery
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Weber, MD
SUNY Downstate Health Sciences University
Jared Jagdeo, MD
SUNY Downstate Health Sciences University
John Danias, MD, PhD
SUNY Downstate Health Sciences University
Ellen Ginzler, MD
SUNY Downstate Health Sciences University
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”